Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combinathin therapy with tofogliflozin and anagliptin in type 2 diabetic patients
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Anagliptin (Primary) ; Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 04 Sep 2017 New trial record